Contrasting Metsera (MTSR) & The Competition

Metsera (NASDAQ:MTSR) is one of 617 public companies in the “MED – BIOMED/GENE” industry, but how does it weigh in compared to its peers? We will compare Metsera to related companies based on the strength of its risk, analyst recommendations, institutional ownership, valuation, profitability, dividends and earnings.

Earnings & Valuation

This table compares Metsera and its peers top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Metsera	N/A	-$209.13 million	-11.16
Metsera Competitors	$956.34 million	-$45.07 million	11.71

Metsera’s peers have higher revenue and earnings than Metsera. Metsera is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Metsera and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Metsera	N/A	-121.12%	-53.54%
Metsera Competitors	-1,425.24%	-589.70%	-28.85%

Institutional & Insider Ownership

51.3% of shares of all “MED – BIOMED/GENE” companies are held by institutional investors. 13.6% of shares of all “MED – BIOMED/GENE” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Metsera and its peers, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Metsera	1	3	4	0	2.38
Metsera Competitors	5932	12240	37705	1175	2.60

Metsera currently has a consensus target price of $55.75, indicating a potential downside of 20.92%. As a group, “MED – BIOMED/GENE” companies have a potential upside of 50.47%. Given Metsera’s peers stronger consensus rating and higher possible upside, analysts clearly believe Metsera has less favorable growth aspects than its peers.

Summary

Metsera peers beat Metsera on 10 of the 12 factors compared.

Metsera Company Profile

Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell in 2022 and is headquartered in New York.